“We at Hologic feel incredibly proud to be right on the leading edge of testing breakthroughs that will help lead the world out of this COVID-19 pandemic”
Steve MacMillan, Chairman, President and CEO of Hologic
In response to the current COVID-19 pandemic and to further support our customers, we’ve consolidated the information and resources below to keep you informed. As the situation continues to evolve, we will update this page with more information.
Additional Support
Maurice Exner
“I am so proud of the team’s ability to rise to the challenge and excel on every aspect of the project. The cross-functional teamwork was amazing, and when we put the incredible talent we have together with unprecedented focus, determination and collaboration, it speaks to why the team was able to reach this outstanding achievement so quickly.” Maurice Exner – VP of R&D, Assay Development and Clinical Affairs, Diagnostic Solutions Division
Joshua Moberly
“I began working on the COVID-19 test as soon as the first coronavirus genome was published... The enthusiasm we felt as a group was contagious; everyone volunteered extra time and energy to get this test out as soon as possible. Knowing that our work would have a direct impact in the fight against the coronavirus motivated us to put forth our best efforts.” -Joshua Moberly, Scientist 2, Diagnostic Assay Development
Abby Gajewski-Schwoch
“My favorite aspect of this project is how everyone from all functional areas came together to execute as quickly as possible, bringing a critically needed product to market with unprecedented speed. A united front is a POWERFUL thing!” Abby Gajewski-Schwoch – Director of Panther Fusion Assay Marketing, Diagnostic Solutions Division
Danielle Scelfo
“I am most proud that our team was able to work with the Centers for Medicare and Medicaid Services, Palmetto MolDx and our industry customers, Quest and Lab Corp, to establish a CPT code and appropriate reimbursement rate in an unprecedented amount of time. This will enable our patients to gain immediate access to COVID-19 testing covered by their insurance companies.” Danielle Scelfo – Senior Director of Health Policy and Reimbursement
We are so proud of our R&D and manufacturing teams who are so hard at work getting #COVID19 diagnostic tests into the hands of those who need them. Take an inside look at how the tests are prepared and produced in our lab. Learn more: https://bit.ly/2wggtdP
Thanks to our customer @UW Virology Lab for working long hours and being on the front line in getting patients’ tests processed. We applaud you for making a difference in #COVID-19 testing.
On Monday, we were granted Emergency Use Authorization for our molecular diagnostic test for #coronavirus. The @sdut reports on how our Panther Fusion technology is helping in the fight against #COVID19:
In an interview with @BloombergTV, CEO Steve MacMillan shares how we’re supporting the fight against #COVID19 with tens of thousands of our Panther Fusion molecular #diagnostic tests expected to ship this month. Learn more:
Today, the @US_FDA granted Emergency Use Authorization for our Panther Fusion® SARS-CoV-2 assay, a molecular #diagnostic test which identifies the virus causing #COVID19: Learn more here: https: https://bit.ly/2TTc09A
Additional media coverage
BARDA: HHS Supports Development of First High-Throughput COVID-19 Diagnostic Test
KUSI: San Diego-based Hologic develops test for COVID-19
The Street: Hologic Ramps Up Coronavirus Test Kit Production
The San Diego Union-Tribune: 2 More San Diego Companies Get Emergency Approval to Produce Coronavirus Tests
Boston Herald: Coronavirus Test Developed by Marlboro-Based Hologic Gets Emergency Approval
MassDevice: Hologic Gets U.S. Funding for Coronavirus Test
FierceBiotech: BARDA Backs Development of Hologic's High-Throughput Coronavirus Test
GenomeWeb: Hologic to Receive $699K from BARDA for Rapid Development of High-Throughput Coronavirus Test
San Diego Business Journal: Companies Scale Up Production of COVID-19 Tests
